Nutriband (Nutriband) FCF Margin % : -136.76% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nutriband FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nutriband's Free Cash Flow for the three months ended in Jan. 2024 was $-0.72 Mil. Nutriband's Revenue for the three months ended in Jan. 2024 was $0.53 Mil. Therefore, Nutriband's FCF Margin % for the quarter that ended in Jan. 2024 was -136.76%.

As of today, Nutriband's current FCF Yield % is -9.58%.

The historical rank and industry rank for Nutriband's FCF Margin % or its related term are showing as below:

NTRB' s FCF Margin % Range Over the Past 10 Years
Min: -452.65 Med: -187.51 Max: -31.46
Current: -169.22

During the past 9 years, the highest FCF Margin % of Nutriband was -31.46%. The lowest was -452.65%. And the median was -187.51%.

NTRB's FCF Margin % is ranked worse than
52.35% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs NTRB: -169.22

Nutriband FCF Margin % Historical Data

The historical data trend for Nutriband's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband FCF Margin % Chart

Nutriband Annual Data

Trend

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

FCF Margin %

Get a 7-Day Free Trial

-240.97

-31.46

-203.31

-147.40

-171.70

Nutriband Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-156.06	-157.86	-151.68	-248.60	-136.76

Competitive Comparison of Nutriband's FCF Margin %

For the Biotechnology subindustry, Nutriband's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutriband's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nutriband's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nutriband's FCF Margin % falls into.

Nutriband FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nutriband's FCF Margin for the fiscal year that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jan. 2024 )	/	Revenue (A: Jan. 2024 )
	=	-3.58	/	2.085
	=	-171.70 %

Nutriband's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-0.718	/	0.525
	=	-136.76 %

Nutriband FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nutriband's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

9WV:Germany

Address

121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801

Website

https://www.nutriband.com

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Executives

Michael Davidov	director	60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik	director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan	director, 10 percent owner, officer: CEO	6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros	director, 10 percent owner, officer: Chairman of the BOD	GREGERSTR 36B, FISHAMEND C4 2401